3 transcripts
MDAI
Earnings call transcript
NASDAQ
2024 Q2
12 Aug 24
and an established market leader. Under the MOU, PolyNovo will support our application to the Australian Special Access Scheme or SAS with a goal
MDAI
Earnings call transcript
NASDAQ
2024 Q1
7 May 24
our enrollment goal. This is expected to be the final clinical trial for burn before seeking FDA approval in 2025.
For diabetic foot ulcers or DFUs
MDAI
Earnings call transcript
NASDAQ
2023 Q4
27 Mar 24
is burn and DFUs, however, we believe that the platform can over time, support multiple clinical indications.
Our goal remains for the DeepView System
- Prev
- 1
- Next